On September 21, 2023, Cyclo Therapeutics, Inc., a clinical-stage biotechnology company focused on developing transformative therapies for rare and neurological diseases with limited treatment options, and Applied Molecular Transport Inc. (AMT), a biopharmaceutical company, announced that the companies have entered into a definitive agreement pursuant to which AMT will merge with Cyclo Therapeutics in an all-stock transaction. Wilson Sonsini Goodrich and Rosati is advising AMT on the transaction.

Following the closing of the merger, the combined company will operate under the name “Cyclo Therapeutics, Inc.” and will continue trading on The Nasdaq Capital Market under the ticker symbol “CYTH.” The combined company will focus on advancing Cyclo Therapeutics’ pivotal Phase 3 global study (TransportNPC™) evaluating Trappsol® Cyclo™ for Niemann-Pick Disease Type C1 (NPC1). The transaction is currently expected to close in the fourth quarter of 2023.

The Wilson Sonsini team advising AMT on the transaction includes:

Corporate/M&A
Ken Clark
Robert Ishii
Michael Coke
Jackie Hamilton
Christina Poulsen
Stacy Lee
Eleanor Bleecker
Austin Wolfe
Rachel Nagashima
Zachary Lenox
Kym Tisder
Marianne Stark Bradley

Patents and Innovations
Maya Skubatch
Rex Watkins
Jeff Seidel
Julia Kennedy-Darling

Technology Transactions
Miranda Biven
Adam Kaldor

Tax
Myra Sutanto Shen
Anjali Krishnan

Employee Benefits
Scott McCall
Michael Klippert

Privacy and Cybersecurity
Matthew Staples
Daniel Chen
Michael O’Brien
Dantam Le

Employment Law
Aren Balabanian
Neil Gulyako

Regulatory
Eva Yin

Real Estate
Susan Reinstra
Martin Sul
Sean Wilkinson

For more information, please see the companies' joint press release.